Hartl W H, Demmelmair H, Jauch K W, Schmidt H L, Koletzko B, Schildberg F W
Department of Surgery, Klinikum Grosshadern, Munich, Germany.
Am J Physiol. 1997 May;272(5 Pt 1):E796-802. doi: 10.1152/ajpendo.1997.272.5.E796.
Previous studies on human colorectal tumor protein synthesis in situ relied on techniques that required intra- or perioperative sampling to obtain a sufficient biopsy size. The purpose of the present study was to develop a new technique by use of new mass spectrometry equipment [capillary gas chromatography (GC)-combustion isotope ratio mass spectrometry (IRMS)], which allows reduction of the necessary sampling size. Thereby, tumor sampling could be done via conventional rectosigmoidoscopy, excluding the need for further disturbing invasive measures. Fifteen postabsorptive patients with localized rectal cancer received a primed-constant infusion of [1-13C]leucine (0.16 mumol.kg-1.min-1 constant, 9.6 mumol/kg prime). Forceps biopsies were taken after 3 and 6 h. In five subjects, tumor tissue and normal mucosa were studied simultaneously. Determination of protein-bound leucine enrichment was done by GC-IRMS, and GC-quadrupole MS was used to determine tracer-to-tracee ratios (tracer/tracee) for free intracellular leucine. GC-MS data demonstrated achievement of a steady state in the precursor pool enrichment after 3 h of isotope infusion (tracer/tracee at 3 h: 6.34 +/- 0.46%, at 6 h: 6.58 +/- 0.38%). Calculation of tumor protein synthesis yielded a fractional synthetic rate (FSR) of 1.06 +/- 0.11%/h or 25.5 +/- 2.6%/day (range 12.0-37.1%/day). At any time, protein-bound leucine enrichment was significantly higher in tumor tissue than in normal mucosa of the same subject. However, protein synthetic rates were comparable (tumor: 1.09 +/- 0.20%/h, mucosa: 1.29 +/- 0.28%/h). Thus combined GC-combustion IRMS and GC-/quadrupole MS provide a simple, reliable, and minimally invasive method to determine tumor FSR in situ, thereby excluding interferences common to previous methods. Tumor and mucosa tissues are similar with respect to protein synthesis, but they apparently differ with respect to leucine extraction from the arterial blood.
以往关于人类结肠直肠肿瘤原位蛋白质合成的研究依赖于需要在手术中或围手术期取样以获得足够活检大小的技术。本研究的目的是利用新的质谱设备[毛细管气相色谱(GC)-燃烧同位素比率质谱(IRMS)]开发一种新技术,该技术可减少所需的取样大小。因此,肿瘤取样可通过传统的直肠乙状结肠镜检查进行,无需进一步采取干扰性侵入性措施。15名吸收后状态的局限性直肠癌患者接受了[1-13C]亮氨酸的首剂恒速输注(0.16 μmol·kg-1·min-1恒速,9.6 μmol/kg首剂)。在3小时和6小时后进行钳取活检。在5名受试者中,同时研究肿瘤组织和正常黏膜。通过GC-IRMS测定蛋白质结合亮氨酸的富集情况,并使用GC-四极杆质谱测定游离细胞内亮氨酸的示踪剂与被示踪剂比率(示踪剂/被示踪剂)。GC-MS数据表明,同位素输注3小时后前体池富集达到稳态(3小时时示踪剂/被示踪剂:6.34±0.46%,6小时时:6.58±0.38%)。肿瘤蛋白质合成的计算得出分数合成率(FSR)为1.06±0.11%/小时或25.5±2.6%/天(范围为12.0 - 37.1%/天)。在任何时候,同一受试者肿瘤组织中蛋白质结合亮氨酸的富集均显著高于正常黏膜。然而,蛋白质合成速率相当(肿瘤:1.09±0.20%/小时,黏膜:1.29±0.28%/小时)。因此,结合GC-燃烧IRMS和GC/四极杆质谱提供了一种简单、可靠且微创的方法来原位测定肿瘤FSR,从而排除了以往方法常见的干扰。肿瘤和黏膜组织在蛋白质合成方面相似,但它们在从动脉血中提取亮氨酸方面显然不同。